48. Chakraborti PK, Matange N, Nandicoori VK, Singh Y, Tyagi JS, Visweswariah SS (2011)
Signalling mechanisms in Mycobacteria. Tuberculosis 91:432–440
49. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK,
Sherman DR (2003) Rv3133c/dosR is a transcription factor that mediates the hypoxic
response of Mycobacterium tuberculosis. Mol Microbiol 48:833–843
50. Shiloh MU, Manzanillo P, Cox JS (2008) Mycobacterium tuberculosis senses host-derived
carbon monoxide during macrophage infection. Cell Host Microbe 3:323–330
51. Taneja NK, Dhingra S, Mittal A, Naresh M, Tyagi JS (2010) Mycobacterium tuberculosis
transcriptional adaptation, growth arrest and dormancy phenotype development is triggered
by vitamin C. PLoS ONE 5:e10860
52. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR,
Schoolnik GK (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium
tuberculosis dormancy program. J Exp Med 198:705–713
53. Kaur K, Taneja NK, Dhingra S, Tyagi JS (2014) DevR (DosR) mimetic peptides impair
transcriptional regulation and survival of Mycobacterium tuberculosis under hypoxia by
inhibiting the autokinase activity of DevS sensor kinase. BMC Microbiol 14:195
54. Gupta RK, Thakur TS, Desiraju GR, Tyagi JS (2009) Structure-based design of DevR
inhibitor active against nonreplicating Mycobacterium tuberculosis. J Med Chem 52:6324–
6334
55. Fernandez P, Saint-Joanis B, Barilone N, Jackson M, Gicquel B, Cole ST, Alzari PM (2006)
The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth. J Bacteriol
188:7778–7784
56. Lougheed KE, Osborne SA, Saxty B, Whalley D, Chapman T, Bouloc N, Chugh J, Nott TJ,
Patel D, Spivey VL (2011) Effective inhibitors of the essential kinase PknB and their
potential as anti-mycobacterial agents. Tuberculosis 91:277–286
57. Singh N, Tiwari S, Srivastava KK, Siddiqi MI (2015) Identification of novel inhibitors of
Mycobacterium tuberculosis PknG using pharmacophore based virtual screening, docking,
molecular dynamics simulation, and their biological evaluation. J Chem Inf Model 55:1120–
1129
58. Chiaradia LD, Mascarello A, Purificação M, Vernal J, Cordeiro MNS, Zenteno ME,
Villarino A, Nunes RJ, Yunes RA, Terenzi H (2008) Synthetic chalcones as efficient
inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Bioorg Med
Chem Lett 18:6227–6230
59. Tan LP, Wu H, Yang P-Y, Kalesh KA, Zhang X, Hu M, Srinivasan R, Yao SQ (2009)
High-throughput discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B
(MptpB) inhibitors using click chemistry. Org Lett 11:5102–5105
60. Wong D, Bach H, Sun J, Hmama Z, Av-Gay Y (2011) Mycobacterium tuberculosis protein
tyrosine phosphatase (PtpA) excludes host vacuolar-H + –ATPase to inhibit phagosome
acidification. Proc Natl Acad Sci 108:19371–19376
61. Sharma A, Khuller GK, Sharma S (2009) Peptide deformylase–a promising therapeutic
target for tuberculosis and antibacterial drug discovery. Expert opinion on therapeutic targets
13:753–765
62. Serero A, Giglione C, Sardini A, Martinez-Sanz J, Meinnel T (2003) An unusual peptide
deformylase features in the human mitochondrial N-terminal methionine excision pathway.
J Biol Chem 278:52953–52963
63. Cynamon MH, Alvirez-Freites E, Yeo AE (2004) BB-3497, a peptide deformylase inhibitor,
is active against Mycobacterium tuberculosis. J Antimicrob Chemother 53:403–405
64. Lofland D, Difuntorum S, Waller A, Clements JM, Weaver MK, Karlowsky JA, Johnson K
(2004) In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.
J Antimicrob Chemother 53:664–668
65. Sharma A, Sharma S, Khuller G, Kanwar A (2009) In vitro and ex vivo activity of peptide
deformylase inhibitors against Mycobacterium tuberculosis H37Rv. Int J Antimicrob Agents
34:226–230
340
A. C. Pushkaran et al.
Signalling mechanisms in Mycobacteria. Tuberculosis 91:432–440
49. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK,
Sherman DR (2003) Rv3133c/dosR is a transcription factor that mediates the hypoxic
response of Mycobacterium tuberculosis. Mol Microbiol 48:833–843
50. Shiloh MU, Manzanillo P, Cox JS (2008) Mycobacterium tuberculosis senses host-derived
carbon monoxide during macrophage infection. Cell Host Microbe 3:323–330
51. Taneja NK, Dhingra S, Mittal A, Naresh M, Tyagi JS (2010) Mycobacterium tuberculosis
transcriptional adaptation, growth arrest and dormancy phenotype development is triggered
by vitamin C. PLoS ONE 5:e10860
52. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR,
Schoolnik GK (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium
tuberculosis dormancy program. J Exp Med 198:705–713
53. Kaur K, Taneja NK, Dhingra S, Tyagi JS (2014) DevR (DosR) mimetic peptides impair
transcriptional regulation and survival of Mycobacterium tuberculosis under hypoxia by
inhibiting the autokinase activity of DevS sensor kinase. BMC Microbiol 14:195
54. Gupta RK, Thakur TS, Desiraju GR, Tyagi JS (2009) Structure-based design of DevR
inhibitor active against nonreplicating Mycobacterium tuberculosis. J Med Chem 52:6324–
6334
55. Fernandez P, Saint-Joanis B, Barilone N, Jackson M, Gicquel B, Cole ST, Alzari PM (2006)
The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth. J Bacteriol
188:7778–7784
56. Lougheed KE, Osborne SA, Saxty B, Whalley D, Chapman T, Bouloc N, Chugh J, Nott TJ,
Patel D, Spivey VL (2011) Effective inhibitors of the essential kinase PknB and their
potential as anti-mycobacterial agents. Tuberculosis 91:277–286
57. Singh N, Tiwari S, Srivastava KK, Siddiqi MI (2015) Identification of novel inhibitors of
Mycobacterium tuberculosis PknG using pharmacophore based virtual screening, docking,
molecular dynamics simulation, and their biological evaluation. J Chem Inf Model 55:1120–
1129
58. Chiaradia LD, Mascarello A, Purificação M, Vernal J, Cordeiro MNS, Zenteno ME,
Villarino A, Nunes RJ, Yunes RA, Terenzi H (2008) Synthetic chalcones as efficient
inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Bioorg Med
Chem Lett 18:6227–6230
59. Tan LP, Wu H, Yang P-Y, Kalesh KA, Zhang X, Hu M, Srinivasan R, Yao SQ (2009)
High-throughput discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B
(MptpB) inhibitors using click chemistry. Org Lett 11:5102–5105
60. Wong D, Bach H, Sun J, Hmama Z, Av-Gay Y (2011) Mycobacterium tuberculosis protein
tyrosine phosphatase (PtpA) excludes host vacuolar-H + –ATPase to inhibit phagosome
acidification. Proc Natl Acad Sci 108:19371–19376
61. Sharma A, Khuller GK, Sharma S (2009) Peptide deformylase–a promising therapeutic
target for tuberculosis and antibacterial drug discovery. Expert opinion on therapeutic targets
13:753–765
62. Serero A, Giglione C, Sardini A, Martinez-Sanz J, Meinnel T (2003) An unusual peptide
deformylase features in the human mitochondrial N-terminal methionine excision pathway.
J Biol Chem 278:52953–52963
63. Cynamon MH, Alvirez-Freites E, Yeo AE (2004) BB-3497, a peptide deformylase inhibitor,
is active against Mycobacterium tuberculosis. J Antimicrob Chemother 53:403–405
64. Lofland D, Difuntorum S, Waller A, Clements JM, Weaver MK, Karlowsky JA, Johnson K
(2004) In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.
J Antimicrob Chemother 53:664–668
65. Sharma A, Sharma S, Khuller G, Kanwar A (2009) In vitro and ex vivo activity of peptide
deformylase inhibitors against Mycobacterium tuberculosis H37Rv. Int J Antimicrob Agents
34:226–230
340
A. C. Pushkaran et al.